These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30819926)

  • 21. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
    Lee SR; Choi H; Lee BH; Kang KW; Yu ES; Kim DS; Park Y; Choi CW; Kim BS; Sung HJ
    Korean J Intern Med; 2019 Nov; 34(6):1333-1346. PubMed ID: 30360024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
    Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
    Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
    Larocca A; Mina R; Offidani M; Liberati AM; Ledda A; Patriarca F; Evangelista A; Spada S; Benevolo G; Oddolo D; Innao V; Cangiolosi C; Bernardini A; Musto P; Amico V; Fraticelli V; Paris L; Giuliani N; Falcone AP; Zambello R; De Paoli L; Romano A; Palumbo A; Montefusco V; Hájek R; Boccadoro M; Bringhen S
    Haematologica; 2020 Apr; 105(4):1074-1080. PubMed ID: 31248973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
    Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.
    Fujisaki T; Ishikawa T; Takamatsu H; Suzuki K; Min CK; Lee JH; Wang J; Carson R; Crist W; Qi M; Nagafuji K
    Ann Hematol; 2019 Dec; 98(12):2805-2814. PubMed ID: 31620815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
    San-Miguel J; Bladé J; Shpilberg O; Grosicki S; Maloisel F; Min CK; Polo Zarzuela M; Robak T; Prasad SV; Tee Goh Y; Laubach J; Spencer A; Mateos MV; Palumbo A; Puchalski T; Reddy M; Uhlar C; Qin X; van de Velde H; Xie H; Orlowski RZ
    Blood; 2014 Jun; 123(26):4136-42. PubMed ID: 24833354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
    Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
    Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma.
    Kim MK; Kim K; Min CK; Kwak JY; Bae SB; Yoon SS; Lee JJ; Kim KH; Nam SH; Mun YC; Kim HJ; Bae SH; Shin HJ; Lee JH; Park JS; Jeong SH; Lee MH; Kim YS; Lee HS; Park KW; Lee WS; Lee SM; Lee JO; Hyun MS; Jo DY; Lim SN; Lee JH; Cho DY; Do YR; Kim JA; Park SK; Kim JS; Kim SJ; Kim H; Yi HG; Moon JH; Choi CW; Kim SH; Joo YD; Kim HG; Kim BS; Park MR; Song MK; Kim SY
    Oncotarget; 2017 Jun; 8(23):37605-37618. PubMed ID: 28402945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
    Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
    Morabito F; Gentile M; Mazzone C; Rossi D; Di Raimondo F; Bringhen S; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci MT; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Montefusco V; Musto P; Cascavilla N; Majolino I; Musolino C; Cavo M; Boccadoro M; Palumbo A
    Blood; 2011 Nov; 118(22):5759-66. PubMed ID: 21951682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.
    Zeng X; Liu Q; Peng L; Peng Y; Yi L; Luo X; Li S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2379-2390. PubMed ID: 33770365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
    Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
    N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
    Spicka I; Mateos MV; Redman K; Dimopoulos MA; Richardson PG
    Immunotherapy; 2011 Sep; 3(9):1033-40. PubMed ID: 21913826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
    Gentile M; Magarotto V; Offidani M; Musto P; Bringhen S; Teresa Petrucci M; Gay F; Larocca A; Uccello G; Petrungaro A; Vigna E; Greco R; Grazia Recchia A; Tripepi G; Ria R; Di Raimondo F; Palumbo A; Morabito F
    Am J Hematol; 2017 Mar; 92(3):244-250. PubMed ID: 28006855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.